The clinical success of the BH3-mimetic venetoclax has generated increasing interest to target BCL2 family proteins in oncology. In this issue of Cancer Cell, Reyna and colleagues demonstrate the potential of a pharmacological activator of the pro-apoptotic protein BAX to suppress acute myeloid leukemia both alone and together with venetoclax.

中文翻译：

---

凋亡，在前期。

BH3模仿性venetoclax的临床成功引起了越来越多的关注，以靶向BCL2家族蛋白在肿瘤学中。在这一期的《癌细胞》中，Reyna及其同事证明了促凋亡蛋白BAX的药理激活剂有可能单独或与venetoclax一起抑制急性髓细胞性白血病。